These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15371669)

  • 1. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation.
    Rimola A; Londoño MC; Guevara G; Bruguera M; Navasa M; Forns X; García-Retortillo M; García-Valdecasas JC; Rodes J
    Transplantation; 2004 Sep; 78(5):686-91. PubMed ID: 15371669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin blockade does not affect fibrosis progression in recurrent hepatitis C after liver transplantation.
    Guillaud O; Gurram KC; Puglia M; Lilly L; Adeyi O; Renner EL; Selzner N
    Transplant Proc; 2013; 45(6):2331-6. PubMed ID: 23953545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantation.
    Fabris C; Toniutto P; Bitetto D; Minisini R; Fornasiere E; Smirne C; Pirisi M
    J Gastroenterol; 2007 Jul; 42(7):543-9. PubMed ID: 17653650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M; Fernandez JR; Suarez MJ; Gastaca M; Bustamante J; Pijoan JI; Montejo M; Valdivieso A; Ruiz P; Gonzalez J; Ortiz de Urbina J
    Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.
    Corey KE; Shah N; Misdraji J; Abu Dayyeh BK; Zheng H; Bhan AK; Chung RT
    Liver Int; 2009 May; 29(5):748-53. PubMed ID: 19220742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histological and clinical outcome after liver transplantation for hepatitis C.
    Shuhart MC; Bronner MP; Gretch DR; Thomassen LV; Wartelle CF; Tateyama H; Emerson SS; Perkins JD; Carithers RL
    Hepatology; 1997 Dec; 26(6):1646-52. PubMed ID: 9398011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Explanted liver inflammatory grade predicts fibrosis progression in hepatitis C recurrence.
    Ghabril M; Dickson RC; Krishna M; Machicao V; Aranda-Michel J; Bonatti H; Nguyen JH
    Liver Transpl; 2011 Jun; 17(6):685-94. PubMed ID: 21618689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
    Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent hepatitis C virus infection and outcome after living-donor liver transplant.
    Satapathy SK; Fiel MI; Vanatta JM; Del Rio Martin J; Schiano TD
    Exp Clin Transplant; 2013 Dec; 11(6):522-9. PubMed ID: 23901801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation.
    Yilmaz N; Shiffman ML; Stravitz RT; Sterling RK; Luketic VA; Sanyal AJ; Mills AS; Contos MJ; Coterell A; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2007 Jul; 13(7):975-83. PubMed ID: 17600360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.
    Song AT; Sobesky R; Vinaixa C; Dumortier J; Radenne S; Durand F; Calmus Y; Rousseau G; Latournerie M; Feray C; Delvart V; Roche B; Haim-Boukobza S; Roque-Afonso AM; Castaing D; Abdala E; D'Albuquerque LA; Duclos-Vallée JC; Berenguer M; Samuel D
    World J Gastroenterol; 2016 May; 22(18):4547-58. PubMed ID: 27182164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scarce influence of corticosteroid boluses on long-term viral load and liver histology in transplanted patients with recurrent hepatitis C.
    Barcena R; Oton E; Barreales M; Castillo M; Blesa C
    Transplant Proc; 2006 Oct; 38(8):2502-4. PubMed ID: 17097981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern?
    Berenguer M; Aguilera V; Prieto M; Carrasco D; Rayón M; San Juan F; Landaverde C; Mir J; Berenguer J
    Liver Transpl; 2003 Nov; 9(11):1152-8. PubMed ID: 14586875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression.
    Toniutto P; Minisini R; Fabris C; De Feo T; Marangoni F; Burlone M; Avellini C; Bitetto D; Fornasiere E; Fumolo E; Baccarani U; Pirisi M
    Clin Transplant; 2009; 23(2):184-90. PubMed ID: 19210526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients.
    Guo L; Orrego M; Rodriguez-Luna H; Balan V; Byrne T; Chopra K; Douglas DD; Harrison E; Moss A; Reddy KS; Williams JW; Rakela J; Mulligan D; Vargas HE
    Liver Transpl; 2006 Apr; 12(4):560-5. PubMed ID: 16555313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of diabetes mellitus and glycemic control on clinical outcomes following liver transplant for hepatitis C.
    Morbitzer KA; Taber DJ; Pilch NA; Meadows HB; Fleming JN; Bratton CF; McGillicuddy JW; Baliga PK; Chavin KD
    Clin Transplant; 2014 Aug; 28(8):862-8. PubMed ID: 24893750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation.
    Toniutto P; Fabris C; Avellini C; Minisini R; Bitetto D; Rossi E; Smirne C; Pirisi M
    World J Gastroenterol; 2005 Oct; 11(38):5944-50. PubMed ID: 16273604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus.
    Taner CB; Bulatao IG; Keaveny AP; Willingham DL; Pungpapong S; Perry DK; Rosser BG; Harnois DM; Aranda-Michel J; Nguyen JH
    Liver Transpl; 2011 Jun; 17(6):641-9. PubMed ID: 21618684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
    Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of hepatitis C infection after liver transplantation.
    Gane EJ; Portmann BC; Naoumov NV; Smith HM; Underhill JA; Donaldson PT; Maertens G; Williams R
    N Engl J Med; 1996 Mar; 334(13):815-20. PubMed ID: 8596547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.